Castle biosciences stock.

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...The Castle Biosciences stock prediction for 2025 is currently $ 28.00, assuming that Castle Biosciences shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 40.19% increase in the CSTL stock price. In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for …

Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ...

Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.

If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Jul 13, 2023 · Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ... Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Europe PMC is an archive of life sciences journal literature. https://orcid.orgUnderstanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.

Jul 7, 2023 · Castle Biosciences (CSTL-0.50%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional Medicare administrative ...

DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)... Nov 24, 2023 · Castle Biosciences Inc CSTL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients …Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) …Mar 20, 2023 · Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholders Castle Biosciences Market Cap: 537.40M, Enterprise value: 484.98M, P/E: -8.76, PEG ratio: 0.08, EPS: -2.84, Revenue: 192.00M, EBITDA: -64.35M, ...Dec 1, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ... Castle Biosciences today announced it has signed a definitive agreement to acquire Cernostics, Inc. ... which may consist entirely of cash or $20 million in cash and $10 million in common stock of ...

In the previous week, Castle Biosciences had 4 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Celcuity. Castle Biosciences' average media sentiment score of 0.35 beat Celcuity's score of -0.30 indicating that Celcuity is being referred to more favorably in the media.

Jean Carruthers Faculty Owner/Co-Owner Founder/Co-Founder: Carruthers Instruments; Consulting Fee: Alastin Skincare, Allergan Aesthetics, Appiell, Avari, Evolus ...Castle Biosciences. Sales (Current Employee) - Friendswood, TX - March 16, 2021. Castle Biosciences is a very culture & mission driven company that genuinely cares for their employees. Working at Castle for almost 5 years now, I can confidently say that I am a valued employee, who is respected as an individual in a company of 240+ employees.At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of …Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver ...Castle Biosciences Inc Stock Earnings The value each CSTL share was expected to gain vs. the value that each CSTL share actually gained. CSTL ( CSTL ) reported Q3 2023 earnings per share (EPS) of -$0.26 , beating estimates of -$0.76 by 66.32% .Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.

Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...

Castle Biosciences stock declined 14% over a five-day trading period ending 3/10/2021, compared to a broader market (S&P500) rise of 2.3%; A change of -14% or more over five trading days is a 4% ...

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. …The estimated Net Worth of Mara G. Aspinall is at least $2.79 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,995,313 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Europe PMC is an archive of life sciences journal literature.Europe PMC is an archive of life sciences journal literature.The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Jun 5, 2023 · Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months. Stock Info Stock Quote Price $19.88 Volume 52,546 Change +0.03 % Change +0.15% Today's Open $19.69 Previous Close $19.85 Intraday High $20.26 Intraday Low $19.69 52-Week High $29.59 52-Week Low $9.26 Pricing delayed by 20 minutes. Last Updated 11/24/2023 1:00 PM ET Stock Chart View stock chart as data table From: To:Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Dec 1, 2023 · CSTL Earnings Date and Information. Castle Biosciences last released its earnings results on November 2nd, 2023. The reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.66. The company earned $61.49 million during the quarter, compared to the consensus estimate of $44.94 million. 19 Nis 2023 ... Castle Biosciences, Inc., a company improving health through innovative ... Stock BITF logo. BITF · Bitfarms Announces C$60 Million Private ...Europe PMC is an archive of life sciences journal literature.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ...The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver ...Instagram:https://instagram. stock quote for spyinvesco mortgage capital incmeta dividendtasty trade review Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ... business presentation trainingmeena flynn Jul 13, 2023 · Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ... 2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)... s ticker The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built.Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...